-+ 0.00%
-+ 0.00%
-+ 0.00%

Telix says ProstACT Global Phase 3 safety data set for ASCO late-breaking oral session

PUBT·04/21/2026 20:49:33
Listen to the news
Telix says ProstACT Global Phase 3 safety data set for ASCO late-breaking oral session
  • Telix flagged preliminary safety and dosimetry findings from Part 1 of its ProstACT Global Phase 3 study as a late-breaking oral presentation at ASCO 2026.
  • Data will be presented June 1, 2026, covering TLX591-Tx used with standard of care in PSMA-positive metastatic castration-resistant prostate cancer.
  • Part 1 supports trial progression by evaluating tolerability, biodistribution, and radiation dose profile in a lead-in setting.
  • ProstACT Global compares TLX591-Tx combined with standard of care versus standard of care alone, aiming to support broad adoption across major markets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211649PRIMZONEFULLFEED9694441) on April 21, 2026, and is solely responsible for the information contained therein.